AB
VERV

Amalgamated Bank’s Verve Therapeutics VERV Stock Holding History

Amalgamated Bank’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,449
Closed -$28K – 3035
2025
Q2 		$28K Hold
2,449
– – ﹤0.01% 1998
2025
Q1 		$11K Buy
2,449
+225
+10% +$1.51K ﹤0.01% 2347
2024
Q4 		$13K Hold
2,224
– – ﹤0.01% 2326
2024
Q3 		$11K Hold
2,224
– – ﹤0.01% 2423
2024
Q2 		$11K Hold
2,224
– – ﹤0.01% 2409
2024
Q1 		$30K Sell
2,224
-2,116
-49% -$28.1K ﹤0.01% 2009
2023
Q4 		$60K Sell
4,340
-483
-10% -$5.99K ﹤0.01% 2170
2023
Q3 		$64K Hold
4,823
– – ﹤0.01% 2147
2023
Q2 		$90K Sell
4,823
-273
-5% -$4.55K ﹤0.01% 2104
2023
Q1 		$73K Sell
5,096
-1,167
-19% -$22.9K ﹤0.01% 2163
2022
Q4 		$121K Buy
6,263
+159
+3% +$4.21K ﹤0.01% 2061
2022
Q3 		$210K Buy
6,104
+1,249
+26% +$39.9K ﹤0.01% 1827
2022
Q2 		$74K Buy
4,855
+457
+10% +$7.08K ﹤0.01% 2300
2022
Q1 		$100K Buy
+4,398
New +$126K ﹤0.01% 2196

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Amalgamated Bank's VERV Position: Q3 2025 in Review

Amalgamated Bank sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 2,449 shares — an estimated $28K sold.

Amalgamated Bank first reported a position in VERV in Q1 2022 and held it in 14 quarters. The position peaked at $210K in Q3 2022. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Amalgamated Bank reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Amalgamated Bank sold 2,449 Verve Therapeutics shares in Q3 2025, an estimated $28K.
  • Amalgamated Bank first reported a position in Verve Therapeutics in Q1 2022 and held it in 14 quarters.
  • Amalgamated Bank's Verve Therapeutics position peaked at $210K in Q3 2022.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Amalgamated Bank's 13F filing for Q3 2025, filed 29 Oct 2025.